Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7075936 | 0.93 | KDR (0.32) | KDR | |
| SCHEMBL7071278 | 0.91 | PPARD (0.34) | PDE3BPDE3A | |
| Hydrochloric Acid SCHEMBL7071485 | 0.83 | ITGB3 (0.34) | — | |
| SCHEMBL7071206 | 0.80 | F10 (0.38) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7075187 | 0.79 | ITGB3 (0.38) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7071204 | 0.79 | GLA (0.33) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7079098 | 0.78 | PDE3B (0.38) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7073413 | 0.72 | F10 (0.38) | PDE3BPDE3A | |
| SCHEMBL7073036 | 0.72 | ITGB3 (0.30) | — | |
| SCHEMBL7075939 | 0.71 | ITGB3 (0.38) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | WYETH (US) | 2003-06-12 | — | — | US | disclosed |
| US-6429214-B1 | INHIBITORS OF BONE RESORPTION | WYETH | 2002-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | ITGAV, ITGB2, ITGB3 | PDE3B 518/4885PDE3A 700/4885PDE4A 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.